Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Nrf2 degradation by the ubiquitin proteasome pathway is inhibited by KIAA0132, the human homolog to INrf2

Abstract

INrf2 tethering of the transcription factor Nrf2 in the cytosol prevents Nrf2 activation of antioxidant response element (ARE) mediated gene expression. This investigation was undertaken to determine if tethering affected Nrf2 degradation. Data is presented showing that Nrf2 is degraded by the ubiquitin-proteasome pathway. Nrf2 co-immunoprecipitated with a HA tagged ubiquitin polymer and accumulated in cells expressing inactive ubiquitin activating enzyme El. Inhibition of proteasome activity resulted in accumulation of Nrf2. The rate of Nrf2 degradation, measured under conditions where the majority of Nrf2 was not tethered, exhibited a T1/2 of approximately 3 h. Over-expression of human INrf2, KIAA0132, blocked Nrf2 conjugation to the ubiquitin polymer and blocked Nrf2 degradation. These results suggest that association of Nrf2 with INrf2 inhibits ubiquitin-proteasome degradation of Nrf2. Maintaining the majority of Nrf2 in a tethered form, resistant to ubiquitin-proteasome dependent degradation, allows a pool of Nrf2 to be available for rapid Nrf2/ARE-dependent gene transcription following stress mediated release from INrf2. Further, the observation that free Nrf2 is degraded by the ubiquitin proteasome pathway provides a potential mechanism by which ARE-dependent gene transcription is attenuated after induction.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Chan JY, Kwong M . 2000 Biochim. Biophys. Acta 1517: 19–26

  • Chanas SA, Jiang Q, McMahon M, McWalter GK, McLellan LI, Elcombe CR, Henderson CJ, Wolfb CR, Moffat GJ, Itoh K, Yamamoto M, Hayes JD . 2002 Biochem. J. 365: Pt2 405–416

  • Chowdary DR, Dermody JJ, Jha KK, Ozer HL . 1994 Mol. Cell. Biol. 14: 1997–2003

  • Ciechanover A . 1998 EMBO J. 17: 7151–7160

  • Dhakshinamoorthy S, Jaiswal AK . 2001 Oncogene 20: 3906–3917

  • Favreau LV, Pickett CB . 1991 J. Biol. Chem. 266: 4556–4561

  • Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL . 1995 Science 268: 726–731

  • Friling RS, Bensimon A, Tichauer Y, Daniel V . 1990 Proc. Natl. Acad. Sci. USA 87: 6258–6262

  • Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, Yamamoto M . 1999 Genes Dev. 13: 76–86

  • Kwak MK, Itoh K, Yamamoto M, Kensler TW . 2002 Mol. Cell. Biol. 22: 2883–2892

  • McMahon M, Itoh K, Yamamoto M, Chanas SA, Henderson CJ, McLellan LI, Wolf CR, Cavin C, Hayes JD . 2001 Cancer Res. 61: 3299–3307

  • Meister A, Anderson ME . 1983 Annu. Rev. Biochem. 52: 711–760

  • Moi P, Chan K, Asunis I, Cao A, Kan YW . 1994 Proc. Natl. Acad. Sci. USA 91: 9926–9930

  • Mulcahy RT, Wartman MA, Bailey HH, Gipp JJ . 1997 J. Biol. Chem. 272: 7445–7454

  • Murakami Y, Matsufuji S, Kameji T, Hayashi S, Igarashi K, Tamura T, Tanaka K, Ichihara A . 1992 Nature 360: 597–599

  • Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, Kensler TW . 2001 Proc. Natl. Acad. Sci. USA 98: 3410–3415

  • Sekhar KR, Soltaninassab SR, Borrelli MJ, Xu ZQ, Meredith MJ, Domann FE, Freeman ML . 2000 Biochem. Biophys. Res. Commun. 270: 311–317

  • Sekhar KR, Spitz DR, Harris S, Nguyen TT, Meredith MJ, Holt JT, Guis D, Marnett LJ, Summar ML, Freeman ML . 2002 Free Radic. Biol. Med. 32: 650–662

  • Sheaff RJ, Singer JD, Swanger J, Smitherman M, Roberts JM, Clurman BE . 2000 Mol. Cell. 5: 403–410

  • Su K, Roos MD, Yang X, Han I, Paterson AJ, Kudlow JE . 1999 J. Biol. Chem. 274: 15194–15202

  • Treier M, Staszewski LM, Bohmann D . 1994 Cell 78: 787–798

  • Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ . 2001 Nature 412: 346–351

  • Wild AC, Gipp JJ, Mulcahy T . 1998 Biochem. J. 332: 373–381

  • Wild AC, Moinova HR, Mulcahy RT . 1999 J. Biol. Chem. 274: 33627–33636

  • Wolf CR . 2001 Proc. Natl. Acad. Sci. USA 98: 2941–2943

  • Xie Y, Varshavsky A . 2000 Proc. Natl. Acad. Sci. USA 97: 2497–2502

Download references

Acknowledgements

It is a pleasure to acknowledge the expert technical assistance of Waraporn Decha-Umphai. This investigation was supported in part by PHS/NIH grants CA-38079 and P30ES00267 pilot project funds.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael L Freeman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sekhar, K., Yan, X. & Freeman, M. Nrf2 degradation by the ubiquitin proteasome pathway is inhibited by KIAA0132, the human homolog to INrf2. Oncogene 21, 6829–6834 (2002). https://doi.org/10.1038/sj.onc.1205905

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205905

Keywords

This article is cited by

Search

Quick links